Evidence map›Paper›PMID 42207426›Full record

ArticleDrug delivery and translational research2026

Oral capsule administration of biomacromolecules that achieves bioavailability and pharmacokinetics comparable to subcutaneous injection in dogs - the BIONDD

Nikolaj Skak, Nina Mertz, Nils Piwon, Martin R Olsen, Ester Caffarel-Salvador, David J Brayden, Jesper Østergaard, Karsten Lindhardt

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nikolaj SkakBioGrail ApS, Langebjerg 1, Roskilde, 4000, Denmark.ORCID http://orcid.org/0009-0009-8124-1124
Nina MertzBioGrail ApS, Langebjerg 1, Roskilde, 4000, Denmark.ORCID http://orcid.org/0000-0003-3543-0433
Nils PiwonBioGrail ApS, Langebjerg 1, Roskilde, 4000, Denmark.ORCID http://orcid.org/0000-0002-1225-5794
Martin R OlsenBioGrail ApS, Langebjerg 1, Roskilde, 4000, Denmark.
Ester Caffarel-SalvadorChiesi Global Rare Diseases, One Boston Place, Suite 4000, Boston, MA, 02108, USA.ORCID http://orcid.org/0000-0002-2844-7598
David J BraydenUCD School of Veterinary Medicine and UCD Conway Institute, University College Dublin, Dublin, D04 V1W8, Ireland.ORCID http://orcid.org/0000-0002-8781-8344
Jesper ØstergaardDepartment of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, DK- 2100, Denmark.ORCID http://orcid.org/0000-0003-3448-4237
Karsten LindhardtBioGrail ApS, Langebjerg 1, Roskilde, 4000, Denmark. kl@biograil.com.ORCID http://orcid.org/0000-0002-5718-4950

Funding

Innovationsfonden 1045-00053BInnovationsfonden 1146-00004
6 · The paper itself

Abstract

Biomacromolecules including peptides, proteins, antibodies, and gene medicines, comprise important classes of therapeutics in treating disease. A drawback of biologics is their inconvenient route of administration, as they are mostly injected. Most patients prefer the oral administration route over injections. To accommodate this need, we developed the BIONDD

Indexed as

BiologicsBiomacromoleculesBIONDD®CapsuleCombination deviceOral administration

Identifiers

PMID42207426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.